152 related articles for article (PubMed ID: 1909635)
41. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
Al-Awadhi A; Olusi S; Al-Zaid N; Prabha K
J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038
[TBL] [Abstract][Full Text] [Related]
42. Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis.
Stevenson DA; Schwarz EL; Viskochil DH; Moyer-Mileur LJ; Murray M; Firth SD; D'Astous JL; Carey JC; Pasquali M
Pediatr Res; 2008 Jun; 63(6):697-701. PubMed ID: 18317233
[TBL] [Abstract][Full Text] [Related]
43. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
[TBL] [Abstract][Full Text] [Related]
44. Biochemical measurements in Paget's disease of bone.
Russell RG; Colwell A; Hannon RA; Blumsohn A; al-Dehaimi AW; Assiri AM; Peel NF; Eastell R
Semin Arthritis Rheum; 1994 Feb; 23(4):240-1. PubMed ID: 8009238
[No Abstract] [Full Text] [Related]
45. Bone resorption in kidney transplant recipients.
Gioviale MC; Damiano G; Lombardo C; Maione C; Buscemi G; Lo Monte AI
Transplant Proc; 2009 May; 41(4):1170-4. PubMed ID: 19460508
[TBL] [Abstract][Full Text] [Related]
46. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
47. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis.
Parviainen MT; Jääskeläinen K; Kröger H; Arnala I; Alhava E
Clin Chim Acta; 1999 Jan; 279(1-2):145-54. PubMed ID: 10064126
[TBL] [Abstract][Full Text] [Related]
48. Components of biological variation of biochemical markers of bone turnover in Paget's bone disease.
Alvarez L; RicOs C; Peris P; GuaNabens N; Monegal A; Pons F; Ballesta AM
Bone; 2000 Jun; 26(6):571-6. PubMed ID: 10831927
[TBL] [Abstract][Full Text] [Related]
49. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease.
Blumsohn A; Naylor KE; Assiri AM; Eastell R
Clin Chem; 1995 Nov; 41(11):1592-8. PubMed ID: 7586548
[TBL] [Abstract][Full Text] [Related]
50. Comparison of urinary bone resorption markers in women of 40-70 years; day-to-day and long-term variation in individual subjects.
Gerrits MI; Vecht-Hart IM; Oldenhave A; Thijssen JH
Maturitas; 1998 Nov; 30(3):247-55. PubMed ID: 9881324
[TBL] [Abstract][Full Text] [Related]
51. [Valve and significance of urinary hydroxyproline in osseous pathology].
Hioco D; Gruson M; Ryckewaert A; de Sèze S
Ann Biol Clin (Paris); 1967; 25(5):725-34. PubMed ID: 6059731
[No Abstract] [Full Text] [Related]
52. Relationship of the activity of the bone isoenzyme of serum alkaline phosphatase to urinary hydroxyproline excretion in metabolic and neoplastic bone diseases.
Stĕpán J; Pacovský V; Horn V; Silinková-Málková E; Vokrouhlická O; Konopásek B; Formánková J; Hrba J; Marek J
Eur J Clin Invest; 1978 Dec; 8(6):373-7. PubMed ID: 105909
[TBL] [Abstract][Full Text] [Related]
53. Quantitative analyses of urinary pyridinoline and deoxypyridinoline excretion in patients with hyperthyroidism.
Ohishi T; Takahashi M; Kushida K; Horiuchi K; Ishigaki S; Inoue T
Endocr Res; 1992; 18(4):281-90. PubMed ID: 1473521
[TBL] [Abstract][Full Text] [Related]
54. Development of an immunoassay for urinary galactosylhydroxylysine.
Leigh SD; Ju HS; Lundgard R; Daniloff GY; Liu V
J Immunol Methods; 1998 Nov; 220(1-2):169-78. PubMed ID: 9839938
[TBL] [Abstract][Full Text] [Related]
55. Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.
Torres R; de la Piedra C; Rapado A
Scand J Clin Lab Invest; 1989 May; 49(3):279-85. PubMed ID: 2787049
[TBL] [Abstract][Full Text] [Related]
56. The origin of urinary hydroxylysyl glycosides in Paget's disease of bone and in primary hyperparathyroidism.
Askenasi R; De Backer M; Devos A
Calcif Tissue Res; 1976 Nov; 22(1):35-40. PubMed ID: 1000341
[TBL] [Abstract][Full Text] [Related]
57. Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism.
LoCascio V; Braga V; Bertoldo F; Bettica P; Pasini AF; Stefani L; Moro L
Clin Endocrinol (Oxf); 1994 Jul; 41(1):47-51. PubMed ID: 8050131
[TBL] [Abstract][Full Text] [Related]
58. [Usefulness of bone remodelling biochemical markers in the diagnosis and follow-up of Paget's bone disease, primary hyperparathyroidism, tumor hypercalcemia, and postmenopausal osteoporosis. II. Bone resorption markers].
de la Piedra Gordo C; Torres Jiménez R
An Med Interna; 1990 Oct; 7(10):534-8. PubMed ID: 2104101
[TBL] [Abstract][Full Text] [Related]
59. Investigations of bone turnover in renal osteopathy.
Müller A; Stein G; Lehmann G; Hein G
Eur J Med Res; 1999 Feb; 4(2):78-84. PubMed ID: 10066644
[TBL] [Abstract][Full Text] [Related]
60. Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases.
Seibel MJ; Duncan A; Robins SP
J Rheumatol; 1989 Jul; 16(7):964-70. PubMed ID: 2769668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
